JP2010538020A5 - - Google Patents

Download PDF

Info

Publication number
JP2010538020A5
JP2010538020A5 JP2010523239A JP2010523239A JP2010538020A5 JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5 JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5
Authority
JP
Japan
Prior art keywords
protein
crystallin
fragment
composition
angiogenic fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010523239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538020A (ja
JP5685773B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2008/001319 external-priority patent/WO2009029991A1/en
Publication of JP2010538020A publication Critical patent/JP2010538020A/ja
Publication of JP2010538020A5 publication Critical patent/JP2010538020A5/ja
Application granted granted Critical
Publication of JP5685773B2 publication Critical patent/JP5685773B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010523239A 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤 Expired - Fee Related JP5685773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007904857 2007-09-07
AU2007904857A AU2007904857A0 (en) 2007-09-07 Agents with angiogenic and wound healing activity
PCT/AU2008/001319 WO2009029991A1 (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Publications (3)

Publication Number Publication Date
JP2010538020A JP2010538020A (ja) 2010-12-09
JP2010538020A5 true JP2010538020A5 (enExample) 2011-10-20
JP5685773B2 JP5685773B2 (ja) 2015-03-18

Family

ID=40428369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010523239A Expired - Fee Related JP5685773B2 (ja) 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤

Country Status (6)

Country Link
US (1) US8404644B2 (enExample)
EP (2) EP2190455A4 (enExample)
JP (1) JP5685773B2 (enExample)
AU (1) AU2008295449A1 (enExample)
NZ (1) NZ583803A (enExample)
WO (1) WO2009029991A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583803A (en) * 2007-09-07 2012-12-21 Ind Res Ltd Agents with angiogenic and wound healing activity
JP2013513622A (ja) * 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
WO2012102100A1 (ja) 2011-01-26 2012-08-02 雪印メグミルク株式会社 感覚改善剤
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
JP2014005254A (ja) * 2012-06-26 2014-01-16 Bfsr:Kk 熱傷由来全身性炎症反応症候群の予防外用薬
PE20151747A1 (es) 2013-03-14 2015-12-18 Univ Massachusetts Metodo para inhibir cataratas y presbicia
KR20170040648A (ko) * 2015-10-05 2017-04-13 차의과학대학교 산학협력단 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물
MX376641B (es) 2015-11-13 2025-03-07 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia.
EP3920971A4 (en) * 2019-02-08 2022-10-05 Auckland Uniservices Limited BIOMATERIALS AND METHODS ASSOCIATED THEREOF

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187482A1 (en) * 1995-10-13 1997-04-14 Eri Inoue Pharmaceutical composition
WO1999051634A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-3
WO1999051738A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-4
EP1121384A1 (en) 1998-10-15 2001-08-08 E.I. Dupont De Nemours And Company Polymers, containing a fluorocyclobutyl ring and their preparation
JP3783200B2 (ja) * 2000-08-24 2006-06-07 株式会社加美乃素本舗 血管新生剤
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
US7263214B2 (en) 2002-05-15 2007-08-28 Ge Medical Systems Global Technology Company Llc Computer aided diagnosis from multiple energy images
AU2003281325A1 (en) 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
JPWO2004096277A1 (ja) * 2003-05-01 2006-07-13 国立大学法人京都大学 眼内血管新生疾患の予防又は治療剤
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
EP1773375A1 (en) * 2004-07-14 2007-04-18 University of Utah Research Foundation Netrin-related compositions and uses
DK1959981T3 (da) 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
WO2006091930A2 (en) 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
EP1978988A4 (en) 2006-01-13 2009-11-04 Univ New York State Res Found PEPTIDE-BASED REGULATION OF GAP-JUNCTIONS
WO2008005021A1 (en) * 2006-06-30 2008-01-10 The Johns Hopkins University Use of crystallin for the modulation of angiogenesis
EP2091557A2 (en) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
EP2104511A4 (en) 2006-12-11 2010-06-09 Univ Leland Stanford Junior ALPHA-B-CRYSTALLINE AS THERAPY AGAINST INFLAMMATION
WO2009012224A2 (en) 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
NZ583803A (en) * 2007-09-07 2012-12-21 Ind Res Ltd Agents with angiogenic and wound healing activity

Similar Documents

Publication Publication Date Title
JP2010538020A5 (enExample)
JP2014530220A5 (enExample)
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
JP2010222367A5 (enExample)
JP2012041342A5 (enExample)
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
JP2013155188A5 (enExample)
NO20084187L (no) Medikamenter og proteiner
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
CO6640218A2 (es) Heterociclilbencillporazoles sustituidos y uso de los mismos
JP2014530873A5 (enExample)
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
CO7310526A2 (es) Composición farmaceútica oral en forma de microesferas y proceso de elaboración
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
CU20160088A7 (es) Piperidinil-tetrahidroquinolinas sustituidas
NZ583803A (en) Agents with angiogenic and wound healing activity
CR20160277A (es) Piperidinil tetrahidroquinolinas sustituidas
DK1988909T3 (da) Anvendelse af polyethylenglycol til inflammationsbeslægtede topiske lidelser eller sygdomme og sårheling
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
MX2014008521A (es) Combinacion de beta-hidroxi-beta-metil-butirato, arginina y glutamina, para usarse en el tratamiento de ulceras diabeticas.
UY28953A1 (es) Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
SV2010003578A (es) Oxazolidinonas para el tratamiento y profilaxis de la insuficiencia cardiaca
JP2011012060A5 (enExample)
AR077427A1 (es) Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st
RU2008106606A (ru) Марля, пропитанная лекарственным средством